Clinical Collaboration Agreement between Teva And Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Rescue Inhaler Respiratory Program; Teva And Abingworth Enter Strategic Development Funding Agreement To Provide Up To $150M To Offset Program Costs And To Accelerate Clinical Research For Teva's TEV-'248 Program
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. (TEVA) and Launch Therapeutics have entered a clinical collaboration to accelerate the development of Teva's Dual-Action Asthma Rescue Inhaler (TEV-‘248). Additionally, Teva and Abingworth, part of Carlyle (CG), announced a strategic development funding agreement providing Teva up to $150 million to support the TEV-‘248 program. This collaboration aims to expedite the clinical research program, with Launch Therapeutics leading the operational execution of clinical trials. Teva retains responsibility for manufacturing, U.S. regulatory interactions, and commercialization. The funding from Abingworth will be recognized by Teva as a reduction in R&D expenses, and Abingworth is eligible for payments based on sales if TEV-‘248 receives FDA approval.

April 01, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Carlyle's (CG) involvement through Abingworth in funding Teva's TEV-‘248 program highlights its strategic investment in healthcare innovation, potentially enhancing its investment portfolio's value.
Carlyle's investment in Teva's TEV-‘248 through Abingworth demonstrates a strategic focus on healthcare innovation. This investment could yield significant returns if TEV-‘248 is successful, enhancing Carlyle's portfolio value and showcasing its commitment to advancing healthcare solutions.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
Teva's collaboration with Launch Therapeutics and funding agreement with Abingworth could accelerate the development of its innovative asthma inhaler, TEV-‘248, potentially leading to a faster market entry and revenue generation.
The collaboration and funding are directly aimed at accelerating the development and commercialization of TEV-‘248, which could significantly impact Teva's position in the respiratory care market. The potential for TEV-‘248 to be the first Dual-Action Asthma Rescue Inhaler for both adult and pediatric indications presents a substantial market opportunity.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90